Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Wulf

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.
Haematologica|October 12, 2019
Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Journal of Hematology & Oncology|February 21, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working partyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Frontiers in Immunology|May 1, 2020
Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.
Haematologica|October 12, 2019
Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Journal of Hematology & Oncology|February 21, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working partyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Frontiers in Immunology|May 1, 2020
Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Pageof 14